Conference Coverage

Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients


 

REPORTING FROM ASH 2019

Safety

“Nearly all patients had a serious adverse event, which was typically admission to the hospital for neutropenic fever,” Dr. Cowan said.

One patient experienced dose-limiting toxicity and died at day 33. The patient had a disseminating fungal infection, grade 4 cytokine release syndrome (CRS), and neurotoxicity. The patient’s death prompted the researchers to include performance status in the study’s eligibility criteria.

All patients developed CRS. Only the aforementioned patient had grade 4 CRS, and three patients had grade 3 CRS. Six patients experienced neurotoxicity. There were no cases of tumor lysis syndrome.

Efficacy

“All patients experienced an increase of cells expressing BCMA,” Dr. Cowan said. “While there was significant variability in BCMA expression at baseline, all cells expressed BCMA after three doses of the gamma secretase inhibitor.”

The median BCMA expression after JSMD194 treatment was 99% (range, 96%-100%), and there was a median 20-fold (range, 8- to 157-fold) increase in BCMA surface density.

The overall response rate was 100%. Two patients achieved a stringent complete response (CR), one achieved a CR, five patients had a very good partial response, and two had a partial response.

The patient with a CR received the 50 x 106 dose of CAR T cells, and the patients with stringent CRs received the 150 x 106 and 300 x 106 doses.

Of the three patients who previously received BCMA-directed therapy, two achieved a very good partial response, and one had a partial response.

Nine of the 10 patients are still alive and in response, with a median follow-up of 20 weeks. The longest follow-up is 444 days.

“To date, all patients have evidence of durable responses,” Dr. Cowan said. “Moreover, all patients had dramatic reductions in involved serum free light chain ... and serum monoclonal proteins.”

Dr. Cowan noted that longer follow-up is needed to assess CAR T-cell persistence and the durability of response.

This trial is sponsored by the Fred Hutchinson Cancer Research Center in collaboration with the National Cancer Institute. Two researchers involved in this work are employees of Juno Therapeutics. Dr. Cowan reported relationships with Juno Therapeutics, Janssen, Celgene, AbbVie, Cellectar, and Sanofi.

SOURCE: Cowan AJ et al. ASH 2019. Abstract 204.

Pages

Recommended Reading

Multiple Myeloma: A New Treatment Option for Newly Diagnosed, Transplant-Ineligible Patients
MDedge Hematology and Oncology
SEER analysis reveals medication adherence factors in newly diagnosed myeloma
MDedge Hematology and Oncology
Levofloxacin prophylaxis improves survival in newly diagnosed myeloma
MDedge Hematology and Oncology
Foundation launches direct-to-patient registry in multiple myeloma
MDedge Hematology and Oncology
Early lenalidomide may delay progression of smoldering myeloma
MDedge Hematology and Oncology
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
MDedge Hematology and Oncology
High complete response rate seen with novel CAR-T for myeloma
MDedge Hematology and Oncology
Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma
MDedge Hematology and Oncology
Myeloma patients over age 70 can benefit from auto-HC transplant
MDedge Hematology and Oncology
D-RVd for frontline myeloma looks robust in GRIFFIN trial update
MDedge Hematology and Oncology